Rx (Prescription Medicine)
USD $ 28.00
Aprecap 150mg Injection 是一种用于治疗特定类型癌症的靶向疗法。其活性成分为 Aprepitant，属于一类称为神经激肽-1（NK1）受体拮抗剂的药物。Aprepitant 通过阻断大脑中一种称为物质 P 的物质的作用，从而防止恶心和呕吐的触发。这使其在预防化疗诱发的恶心和呕吐（CINV），包括急性和延迟性 CINV，以及预防术后恶心和呕吐（PONV）方面尤为有效。
Aprecap 150mg Injection 通常由医护专业人员通过静脉给药。剂量和治疗时长取决于所治疗的具体癌症类型、化疗方案以及患者的个体反应。它常与其他抗呕吐药物联合使用，以提供对恶心和呕吐的全面保护。
常见的不良反应可能包括疲劳、嗝、便秘和食欲不振。严重不良反应虽罕见但可能发生。患者应告知医生任何既往病史，尤其是肝功能问题，以及正在服用的其他药物。Aprecap 150mg Injection 应储存在室温，避光防潮。务必仅在合格医疗专业人员的处方下使用此药。
| Molecule | |
|---|---|
| Strength | |
| Pack Quantity | |
| Medicine Form | |
| Medicine Type | |
| Rx Status | |
| Country Of Origin | |
| Packaging Type | |
| Brand Name |
其他品牌的 Aprepitant 150 Mg — 同一活性成分且强度相同，但来自不同制造商。
医学审核
Renu Meena, B.Pharm
Medical Content Writer
Renu Meena is an experienced Medical Content Writer with a strong foundation in pharmacy practice. She holds a Bachelor of Pharmacy (B.Pharm) degree from Rajasthan University of Health Sciences (RUHS), Jaipur, and is registered with the Rajasthan State Pharmacy Council (Reg. No. 55661). With 4+ years of experience across clinical pharmacy and medical content development, she creates evidence-based content for medicines, diseases, and patient education. Her work is shaped by a strong understanding of pharmacovigilance and regulatory standards, including ICH guidelines, GVP modules, ICD-10/11, and safety reporting requirements. Renu focuses on making complex medical information simple, accurate, and useful for readers while maintaining high quality and compliance.
